White MA, Fong Y, Singh G. Chemotherapy-associated hepatotoxicities. SurgClin North Am. 2016;96(2):207–17.

Google Scholar 

Gangi A, Lu SC. Chemotherapy-associated liver injury in colorectal cancer. Therap Adv Gastroenterol. 2020;13:1–9.

Google Scholar 

Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, Nordlinger B. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery. 2009;145(4):362–71.

PubMed  Google Scholar 

Chun YS, Laurent A, Maru D, Vauthey JN. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 2009;10(3):278–86.

CAS  PubMed  Google Scholar 

Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger B, Gruenberger T. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol. 2008;34(11):1231–6.

CAS  PubMed  Google Scholar 

Robinson SM, Wilson CH, Burt AD, Manas DM, White SA. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol. 2012;19(13):4287–99.

PubMed  PubMed Central  Google Scholar 

Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94(3):274–86.

CAS  PubMed  Google Scholar 

Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer. 1998;77(11):2008–11.

CAS  PubMed  PubMed Central  Google Scholar 

Puente A, Fortea JI, Del Pozo C, Huelin P, Cagigal ML, Serrano M, et al. Porto-sinusoidal vascular disease associated to oxaliplatin: an entity to think about it. Cells. 2019;8(12):1–10.

Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist. 2009;14(11):1095–105.

PubMed  Google Scholar 

Meunier L, Larrey D. Chemotherapy-associated steatohepatitis. Ann Hepatol. 2020;19(6):597–601. https://doi.org/10.1016/j.aohep.2019.11.012.

Article  CAS  PubMed  Google Scholar 

Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009;8(4):225–30. https://doi.org/10.3816/CCC.2009.n.038.

Article  CAS  PubMed  Google Scholar 

Hubert C, Sempoux C, Horsmans Y, Rahier J, Humblet Y, Machiels JP, Ceratti A, Canon JL, Gigot JF. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int. 2007;27(7):938–43. https://doi.org/10.1111/j.1478-3231.2007.01511.x.

Article  CAS  PubMed  Google Scholar 

Ye J, Xie Y, Xu Y, Chen N, Tu Y. Case report: oxaliplatin-induced idiopathic noncirrhotic portal hypertension: a case report and literature review. Front Med (Lausanne). 2023;28(10):1285064. https://doi.org/10.3389/fmed.2023.1285064.

Article  Google Scholar 

Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–24.

PubMed  Google Scholar 

Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24(13):2065–72.

CAS  PubMed  Google Scholar 

Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg. 2009;16(2):137–44.

PubMed  Google Scholar 

Hubert C, Sempoux C, Humblet Y, van den Eynde M, Zech F, Leclercq I, Gigot JF. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxford). 2013;15(11):858–64. https://doi.org/10.1111/hpb.12047.

Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, et al. The addition of bevacizumab to oxaliplatin-based chemotherapy: Impact upon hepatic sinusoidal injury and thrombocytopenia. J Natl Cancer Inst. 2018;110(8):888–94.

PubMed  Google Scholar 

Kudo M, Zheng RQ, Kim SR, Okabe Y, Osaki Y, Iijima H, et al. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. Intervirology. 2008;51(SUPPL. 1):17–26.

PubMed  Google Scholar 

Brown JJ, Naylor MJYN, Yaga N. Imaging of hepatic cirrhosis. Radiology. 1997;202:1–16.

CAS  PubMed  Google Scholar 

Huber A, Ebner L, Heverhagen JT, Christe A. State-of-the-art imaging of liver fibrosis and cirrhosis: a comprehensive review of current applications and future perspectives. Eur J Radiol Open. 2015;2:90–100.

PubMed  PubMed Central  Google Scholar 

de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74. https://doi.org/10.1016/j.jhep.2021.12.022. Erratum in: J Hepatol.

Article  PubMed  Google Scholar 

Vuppalanchi R, Siddiqui MS, Van Natta ML, Hallinan E, Brandman D, Kowdley K, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Abdelmalek M, Doo E. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 2018;67(1):134–44.

PubMed  Google Scholar 

Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24(31):4983–90.

CAS  PubMed  Google Scholar 

Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56(4):430–9.

PubMed  Google Scholar 

Soubrane O, Brouquet A, Zalinski S, Terris B, Brézault C, Mallet V, Goldwasser F, Scatton O. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg. 2010;251(3):454–60. https://doi.org/10.1097/SLA.0b013e3181c79403.

Article  PubMed  Google Scholar 

Sørensen P, Edal AL, Madsen EL, Fenger C, Poulsen MR, Petersen OF. Reversible hepatic steatosis in patients treated with interferon alfa-2A and 5-fluorouracil. Cancer. 1995;75(10):2592–6.

PubMed  Google Scholar 

Vigano L, De Rosa G, Toso C, Andres A, Ferrero A, Roth A, Sperti E, Majno P, Rubbia-Brandt L. Reversibility of chemotherapy-related liver injury. J Hepatol. 2017;67(1):84–91. https://doi.org/10.1016/j.jhep.2017.02.031.

Article  CAS  PubMed  Google Scholar 

Lawal TO, Farris AB, El-Rayes BF, Subramanian RM, Kim HS. Oxaliplatin-induced hepatoportal sclerosis, portal hypertension, and variceal bleeding successfully treated with transjugular intrahepatic portosystemic shunt. Clin Colorectal Cancer. 2012;11(3):224–7. https://doi.org/10.1016/j.clcc.2012.02.002.

Article  CAS  PubMed  Google Scholar 

Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200(6):845–53.

PubMed  Google Scholar 

Flick KF, Al-Temimi MH, Maatman TK, Sublette CM, Swensson JK, Nakeeb A, et al. Hepatic steatosis after neoadjuvant chemotherapy for pancreatic cancer: incidence and implications for outcomes after pancreatoduodenectomy. J Gastrointest Surg. 2020;24(9):2008–14.

CAS  PubMed  PubMed Central  Google Scholar 

Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009;35(5):515–20.

CAS  PubMed  Google Scholar 

Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110(12):2761–7.

PubMed  Google Scholar 

Volk AM, Fritzmann J, Reissfelder C, Weber GF, Weitz J, Rahbari NN. Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases. BMC Cancer. 2016;10(16):84. https://doi.org/10.1186/s12885-016-2095-6.

Article  CAS  Google Scholar